Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Zhengye Biotechnology Holding Ltd maintains a gross margin of 31.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -46.33%, while the net margin is -40.99%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ZYBT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ZYBT competes directly with industry leaders such as BCTX and TVRD. With a market capitalization of $36.48M, it holds a significant position in the sector. When comparing efficiency, ZYBT's gross margin of 31.10% stands against BCTX's N/A and TVRD's N/A. Such benchmarking helps identify whether Zhengye Biotechnology Holding Ltd is trading at a premium or discount relative to its financial performance.
